Improved yeast strains and fermentation process for producing D-lactic acid and L-lactic acid are disclosed. The improvement lead to higher titer, higher yield, shorter time, lower pH, and higher average specific productivity.

The present invention relates to a composition for transmuting a radioactive substance into a non-radioactive substance using complex microorganisms and a method for preparing the composition.

The embodiments of the present disclosure provides a method of co-producing erythritol and arabinose by using a xylose mother liquor, wherein an extract and a raffinate are obtained by separating the xylose mother liquor through a first chromatography, the extract is configured to prepare crystallized xylose, the raffinate and the liquid glucose or crystallized glucose are blended and erythritol is produced by using a Yarrowia lipolytica with high osmotolerant and a high conversion rate. erythritol crystals are obtained by centrifugation and crystallization first by using characteristics of low solubility degree and easy crystallization of the erythritol, the arabinose raffinate having a high content of arabinose is obtained by separating a centrifuged erythritol mother liquor through a second chromatography, and arabinose crystals are obtained based on the arabinose raffinate.

Provided are a fungus-sourced high-temperature neutral Family-45 cullulase as well as a coding gene and application thereof. The cullulase has optimal pH value of 5.5, and optimal temperature of 60 C., has certain enzyme activity in alkaline condition, and has good alkali resistance, maintains about 70% enzyme activity in optimal condition after being processed at 90 C. for 1 hour, maintains about 50% enzyme activity in optimal condition after being processed in boiling water for 1 hour, and can be well applied in c and other fields.

The present invention relates to the unexpected discovery of a new strain of yeast, dubbed GY7B, which is related to, but genetically and phenotypically distinct from, Lachancea thermotolerans. The invention provides methods of brewing sour beer using GY7B, wherein the methods do not require use of lactic acid or lactic acid producing bacteria.

Described are compositions and methods relating to yeast cells having a genetic mutation that give rise to increased alcohol production. Such yeast is well-suited for use in alcohol production to reduce fermentation time and/or increase yields.

In various aspects and embodiments, the invention provides microbial cells and methods for producing advanced glycosylation products from lower glycosylated intermediates. The microbial cell expresses one or more UDP-dependent glycosyl transferase enzymes in the cytoplasm, for glycosylation of the intermediates. When incubating the microbial strain with a plant extract or fraction thereof comprising the intermediates, these glycosylated intermediates are available for further glycosylation by the cell, and the advanced glycosylation products can be recovered from the media and/or microbial cells.

The invention concerns a strain of Saccharomyces bayanus subsp. uvarum identified as SERIUS and deposited at the DBVPG with deposit number 36P. The invention further concerns the use of the strain of Saccharomyces bayanus subsp. uvarum identified as SERIUS (DBVPG 36P) as a food inoculate in the production of foods obtained through alcoholic fermentation, and a selection method for yeast strains of the group Saccharomyces adapted to alcoholic fermentation, particularly of grape, consisting of an isolation step for such yeasts from flowers.

Provided are a fungus-sourced high-temperature neutral Family-45 cullulase as well as a coding gene and application thereof. The cullulase has optimal pH value of 5.5, and optimal temperature of 60 C., has certain enzyme activity in alkaline condition, and has good alkali resistance, maintains about 70% enzyme activity in optimal condition after being processed at 90 C. for 1 hour, maintains about 50% enzyme activity in optimal condition after being processed in boiling water for 1 hour, and can be well applied in c and other fields.

The invention relates to a microbiome-based therapeutic composition comprising an engineered probiotic cell expressing a sulfotransferase and the use of the microbiome-based therapeutic composition in medicine and a therapeutic regimen.